                         SEQUENCE LISTING

<110>  Ramot at Tel-Aviv University Ltd.
       KEDMI, Ranit
       VEIGA, Nuphar
       BENHAR, Itai
       PEER, Dan
 
<120>  MODULAR PLATFORM FOR TARGETED THERAPEUTICS

<130>  70263

<150>  US 62/363,417
<151>  2016-07-18

<160>  18    

<170>  PatentIn version 3.5

<210>  1
<211>  21
<212>  DNA
<213>  Artificial sequence

<220>
<223>  CD45 sense SiRNA sequence


<220>
<221>  misc_feature
<222>  (1)..(2)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (5)..(6)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (10)..(13)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (20)..(21)
<223>  deoxyribonucleotide

<220>
<221>  misc_feature
<222>  (20)..(21)
<223>  phosphorothioate linkages

<400>  1
cuggcugaau uucagagcat t                                                 21


<210>  2
<211>  21
<212>  DNA
<213>  Artificial sequence

<220>
<223>  CD45 anti-sense  SiRNA sequence


<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (20)..(21)
<223>  deoxyribonucleotide

<220>
<221>  misc_feature
<222>  (20)..(21)
<223>  phosphorothioate linkages

<400>  2
ugcucugaaa uucagccagt t                                                 21


<210>  3
<211>  21
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Luc sense SiRNA sequence


<220>
<221>  misc_feature
<222>  (1)..(3)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (7)..(8)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (14)..(17)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (20)..(21)
<223>  deoxyribonucleotide

<220>
<221>  misc_feature
<222>  (20)..(21)
<223>  phosphorothioate linkages

<400>  3
cuuacgcuga guacuucgat t                                                 21


<210>  4
<211>  21
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Luc anti-sense  SiRNA sequence


<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (20)..(21)
<223>  deoxyribonucleotide

<220>
<221>  misc_feature
<222>  (20)..(21)
<223>  phosphorothioate linkages

<400>  4
ucgaaguacu cagcguaagt t                                                 21


<210>  5
<211>  25
<212>  DNA
<213>  Artificial sequence

<220>
<223>  TNF alpha sense SiRNA sequence


<220>
<221>  misc_feature
<222>  (1)..(2)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  2'-OMe-modified nucleotides

<400>  5
gucucagccu cuucucauuc cugct                                             25


<210>  6
<211>  27
<212>  DNA
<213>  Artificial sequence

<220>
<223>  TNF alpha anti-sense SiRNA sequence


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (25)..(27)
<223>  2'-OMe-modified nucleotides

<400>  6
agcaggaaug agaagaggcu gagacau                                           27


<210>  7
<211>  25
<212>  DNA
<213>  Artificial sequence

<220>
<223>  PLK1 sense  SiRNA sequence


<220>
<221>  misc_feature
<222>  (1)..(2)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (4)..(4)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (12)..(12)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (14)..(14)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (18)..(18)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  2'-OMe-modified nucleotides

<400>  7
gcuuaaugac gaguucuuua cuuct                                             25


<210>  8
<211>  27
<212>  DNA
<213>  Artificial sequence

<220>
<223>  PLK1 anti-sense SiRNA sequence


<220>
<221>  misc_feature
<222>  (3)..(3)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (9)..(9)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (11)..(11)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (13)..(13)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (23)..(23)
<223>  2'-OMe-modified nucleotides

<220>
<221>  misc_feature
<222>  (25)..(27)
<223>  2'-OMe-modified nucleotides

<400>  8
agaaguaaag aacucgucau uaagcag                                           27


<210>  9
<211>  20
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Single strand DNA oligonucleotide

<400>  9
ttgtggaagg gctcatgacc                                                   20


<210>  10
<211>  20
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Single strand DNA oligonucleotide

<400>  10
tcttctgggt ggcagtgatg                                                   20


<210>  11
<211>  21
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Single strand DNA oligonucleotide

<400>  11
gcaccaccat caaggactca a                                                 21


<210>  12
<211>  20
<212>  DNA
<213>  Artificial sequence

<220>
<223>  Single strand DNA oligonucleotide

<400>  12
tcgaggctcc agtgaattcg                                                   20


<210>  13
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  first six amino acid of NlpA can be used as an N terminal anchor

<400>  13

Cys Asp Gln Ser Ser Ser 
1               5       


<210>  14
<211>  117
<212>  PRT
<213>  Artificial sequence

<220>
<223>  VH domain of the antibody

<400>  14

Glu Val Gln Leu Leu Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala 
1               5                   10                  15      


Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr 
            20                  25                  30          


Asn Met Asp Trp Val Lys Gln Ser His Glu Lys Ser Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Ile Asn Pro Tyr Ser Gly Asp Thr Ile Tyr Asn His Lys Phe 
    50                  55                  60                  


Lys Asp Lys Ala Thr Leu Thr Val Tyr Lys Ser Ser Asn Ile Ala Tyr 
65                  70                  75                  80  


Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Gly Gly Tyr Asp Tyr Gly Asp His Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Leu Thr Val Ser Ser 
        115         


<210>  15
<211>  107
<212>  PRT
<213>  Artificial sequence

<220>
<223>  amino acid sequence of the VL domain (kappa) of the antibody

<400>  15

Asp Ile Lys Met Thr Gln Ser Pro Ser Ser Met Tyr Ala Ser Leu Gly 
1               5                   10                  15      


Glu Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Asn Ser Tyr 
            20                  25                  30          


Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Ser Pro Lys Thr Leu Ile 
        35                  40                  45              


Tyr Arg Ala Asn Arg Leu Val Asp Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Gln Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Tyr 
65                  70                  75                  80  


Glu Asp Met Gly Ile Tyr Tyr Cys Leu Gln Asp Asp Glu Phe Pro Arg 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 
            100                 105         


<210>  16
<211>  18
<212>  PRT
<213>  Artificial sequence

<220>
<223>  linker sequence of the antibody

<400>  16

Gly Ser Ala Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 
1               5                   10                  15      


Gly Ser 
        


<210>  17
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  short peptide

<400>  17

Cys Asp Asn Ser Ser Ser 
1               5       


<210>  18
<211>  15
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Biotin lygase tag

<400>  18

Leu His His Ile Leu Asp Ala Gln Lys Met Val Trp Asn His Arg 
1               5                   10                  15  


